Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Loma Linda University School of Medicine, California.
Mitomycin C has a documented response rate of 20% to 30% when used as treatment in advanced breast cancer. Because of its delayed and cumulative hematologic toxicity, there has been a reluctance to use this agent. However, by lowering the drug dosage, the hematologic, pulmonary, and renal toxicities have been reduced. The reduced dosage does not appear to have compromised the treatment results.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on